Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Change in Account Payables (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Change in Account Payables data on record, last reported at $669000.0 in Q3 2025.

  • For Q3 2025, Change in Account Payables fell 36.89% year-over-year to $669000.0; the TTM value through Sep 2025 reached $901000.0, up 253.33%, while the annual FY2024 figure was $711000.0, 219.5% up from the prior year.
  • Change in Account Payables reached $669000.0 in Q3 2025 per RANI's latest filing, up from $278000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $1.1 million in Q3 2024 and bottomed at -$663000.0 in Q4 2023.
  • Average Change in Account Payables over 5 years is $101578.9, with a median of $131000.0 recorded in 2022.
  • Peak YoY movement for Change in Account Payables: surged 263.89% in 2022, then tumbled 411.45% in 2023.
  • A 5-year view of Change in Account Payables shows it stood at -$131000.0 in 2021, then tumbled by 63.36% to -$214000.0 in 2022, then tumbled by 209.81% to -$663000.0 in 2023, then skyrocketed by 68.78% to -$207000.0 in 2024, then skyrocketed by 423.19% to $669000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were $669000.0 in Q3 2025, $278000.0 in Q2 2025, and $161000.0 in Q1 2025.